- Home
- GNLX vs COYA Comparison
GNLX vs COYA Comparison
Compare GNLX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | COYA |
|---|---|---|
| Founded | 2001 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.0M | 124.8M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GNLX | COYA |
|---|---|---|
| Price | $2.67 | $4.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $17.25 | $15.80 |
| AVG Volume (30 Days) | ★ 226.5K | 218.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $2.29 | $3.71 |
| 52 Week High | $8.54 | $7.75 |
Technical Indicators
Market Signals| Indicator | GNLX | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 49.43 |
| Support Level | $2.68 | $4.45 |
| Resistance Level | $3.05 | $5.18 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 34.48 | 83.82 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.